N1 lymph node detection in lymph node harvesting in non-small cell lung cancer: Formaldehyde exposure is a drawback?
Lymph node detection
Non-small cell lung cancer
Survival rates
Journal
Journal of cardiothoracic surgery
ISSN: 1749-8090
Titre abrégé: J Cardiothorac Surg
Pays: England
ID NLM: 101265113
Informations de publication
Date de publication:
10 Oct 2023
10 Oct 2023
Historique:
received:
14
04
2023
accepted:
30
09
2023
medline:
2
11
2023
pubmed:
11
10
2023
entrez:
11
10
2023
Statut:
epublish
Résumé
This study aimed to evaluate the effect of lymph node dissection method on staging results, diagnosis of tumor metastasis in single or multiple N1 lymph nodes and survival rates in patients with non-small cell lung cancer (NSCLC). Patients with NSCLC who underwent anatomic resection between September 2014 and October 2019 were examined prospectively. All patients with similar clinico-demographic characteristics were randomly assigned to either the surgical group (n = 83) or the pathology group (n = 87). Lymph node dissection was performed by the surgeon in the surgical group and by the pathologists after formaldehyde exposure in the pathology group. Data were analyzed according to formaldehyde exposure, N1 positivity, and number of N1 positive lymph nodes. There were no significant differences in N1 lymph node positivity between the two groups (p = 0.482). On average 9.08 lymph node sampling was performed in the surgical group and 2.39 in the pathology group (p = 0.0001). Multiple lymph node involvement was significantly higher in the surgical group (P = 0.0001) than in the pathology group. It is easier to detect lymph node involvement without introducing formaldehyde into the sample. We recommend that N1 lymph node dissection be performed on fresh specimens to detect more lymph node involvement.
Identifiants
pubmed: 37817262
doi: 10.1186/s13019-023-02380-5
pii: 10.1186/s13019-023-02380-5
pmc: PMC10566163
doi:
Substances chimiques
Formaldehyde
1HG84L3525
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.
doi: 10.1002/ijc.31937
pubmed: 30350310
Lim W, Ridge CA, Nicholson AG, et al. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant Imaging Med Surg. 2018;8:709–18.
doi: 10.21037/qims.2018.08.02
pubmed: 30211037
pmcid: 6127520
Ettinger DS, Wood DE, Aggarwal C, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. J Natl Compr Canc Netw. 2019;17:1464–72.
doi: 10.6004/jnccn.2019.0059
pubmed: 31805526
Howington JA, Blum MG, Chang AC et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e278S-e313S.
Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–60.
doi: 10.1056/NEJMoa031644
pubmed: 14736927
Winton T, Livingston R, Johnson D, National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States. Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 23; 352: 2589-97.
Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28:29–34.
doi: 10.1200/JCO.2009.24.0333
pubmed: 19933915
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant NavelbineInternational Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:719–27.
doi: 10.1016/S1470-2045(06)70804-X
pubmed: 16945766
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.
doi: 10.1200/JCO.2007.13.9030
pubmed: 18506026
Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–23.
doi: 10.1378/chest.111.6.1718
pubmed: 9187199
Rusch VW, Asamura H, Watanabe H, et al. Members of IASLC Staging Committee. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.
doi: 10.1097/JTO.0b013e3181a0d82e
pubmed: 19357537
Maeshima AM, Tsuta K, Asamura H, et al. Prognostic implication of metastasis limited to segmental (level 13) and/or subsegmental (level 14) lymph nodes in patients with surgically resected nonsmall cell lung carcinoma and pathologic N1 lymph node status. Cancer. 2012;118:4512–8.
doi: 10.1002/cncr.27424
pubmed: 22282325
Jonnalagadda S, Smith C, Mhango G, et al. The number of lymph node metastases as a prognostic factor in patients with N1 non-small cell lung cancer. Chest. 2011;140:433–40.
doi: 10.1378/chest.10-2885
pubmed: 21292754
pmcid: 3148795
Tezel C, Dogruyol T, Alpay L, et al. Prognostic importance of the Lymph Node factor in surgically resected Non-Small Cell Lung Cancer. Thorac Cardiovasc Surg. 2020;68:183–89.
doi: 10.1055/s-0038-1675345
pubmed: 30388719
Wang Wang Z, Yang H, Hao X, et al. Prognostic significance of the N1 classification pattern: a meta-analysis of different subclassification methods. Eur J Cardiothorac Surg. 2021;59:545–53.
doi: 10.1093/ejcts/ezaa388
Varlotto JM, Yao AN, DeCamp MM, et al. Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. Int J Radiat Oncol Biol Phys. 2015;91:765–73.
doi: 10.1016/j.ijrobp.2014.12.028
pubmed: 25752390
Miyoshi K, Mimura T, Iwanaga K, et al. Surgical treatment of clinical N1 non-small cell lung cancer: ongoing controversy over diagnosis and prognosis. Surg Today. 2010;40:428–32.
doi: 10.1007/s00595-008-4072-4
pubmed: 20425545
Zhang Y, Sun Y, Shen L, et al. Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable. Ann Surg Oncol. 2013;20:1949–54.
doi: 10.1245/s10434-012-2829-x
pubmed: 23263905
Zhang YK, Chai ZD, Tan LL, et al. Association of lymph node involvement with the prognosis of pathological T1 invasive non-small cell lung cancer. World J Surg Oncol. 2017;15:64.
doi: 10.1186/s12957-017-1098-3
pubmed: 28302176
pmcid: 5356304
Chen B, Wang X, Yu X, et al. Lymph node metastasis in chinese patients with clinical T1 non-small cell lung cancer: a multicenter real-world observational study. Thorac Cancer. 2019;10:533–42.
doi: 10.1111/1759-7714.12970
pubmed: 30666800
pmcid: 6397906